Effect of xenon and dexmedetomidine as adjuncts for general anesthesia on postoperative emergence delirium after elective cardiac catheterization in children: study protocol for a randomized, controlled, pilot trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
03 Apr 2020
Historique:
received: 07 11 2019
accepted: 04 03 2020
entrez: 5 4 2020
pubmed: 5 4 2020
medline: 20 1 2021
Statut: epublish

Résumé

Emergence delirium, a manifestation of acute postoperative brain dysfunction, is frequently observed after pediatric anesthesia and has been associated with the use of sevoflurane. Both xenon and dexmedetomidine possess numerous desirable properties for the anesthesia of children with congenital heart disease, including hemodynamic stability, lack of neurotoxicity, and a reduced incidence of emergence delirium. Combining both drugs has never been studied as a balanced-anesthesia technique. This combination allows the provision of anesthesia without administering anesthetic drugs against which the Food and Drug Administration (FDA) issued a warning for the use in young children. In this phase-II, mono-center, prospective, single-blinded, randomized, controlled pilot trial, we will include a total of 80 children aged 0-3 years suffering from congenital heart disease and undergoing general anesthesia for elective diagnostic and/or interventional cardiac catheterization. Patients are randomized into two study groups, receiving either a combination of xenon and dexmedetomidine or mono-anesthesia with sevoflurane for the maintenance of anesthesia. The purpose of this study is to estimate the effect size for xenon-dexmedetomidine versus sevoflurane anesthesia with respect to the incidence of emergence delirium in children. We will also describe group differences for a variety of secondary outcome parameters including peri-interventional hemodynamics, emergence characteristics, incidence of postoperative vomiting, and the feasibility of a combined xenon-dexmedetomidine anesthesia in children. Sevoflurane is the most frequently used anesthetic in young children, but has been indicated as an independent risk factor in the development of emergence delirium. Xenon and dexmedetomidine have both been associated with a reduction in the incidence of emergence delirium. Combining xenon and dexmedetomidine has never been described as a balanced-anesthesia technique in children. Our pilot study will therefore deliver important data required for future prospective clinical trials. EudraCT, 2018-002258-56. Registered on 20 August 2018. https://www.clinicaltrialsregister.eu.

Sections du résumé

BACKGROUND BACKGROUND
Emergence delirium, a manifestation of acute postoperative brain dysfunction, is frequently observed after pediatric anesthesia and has been associated with the use of sevoflurane. Both xenon and dexmedetomidine possess numerous desirable properties for the anesthesia of children with congenital heart disease, including hemodynamic stability, lack of neurotoxicity, and a reduced incidence of emergence delirium. Combining both drugs has never been studied as a balanced-anesthesia technique. This combination allows the provision of anesthesia without administering anesthetic drugs against which the Food and Drug Administration (FDA) issued a warning for the use in young children.
METHODS/DESIGN METHODS
In this phase-II, mono-center, prospective, single-blinded, randomized, controlled pilot trial, we will include a total of 80 children aged 0-3 years suffering from congenital heart disease and undergoing general anesthesia for elective diagnostic and/or interventional cardiac catheterization. Patients are randomized into two study groups, receiving either a combination of xenon and dexmedetomidine or mono-anesthesia with sevoflurane for the maintenance of anesthesia. The purpose of this study is to estimate the effect size for xenon-dexmedetomidine versus sevoflurane anesthesia with respect to the incidence of emergence delirium in children. We will also describe group differences for a variety of secondary outcome parameters including peri-interventional hemodynamics, emergence characteristics, incidence of postoperative vomiting, and the feasibility of a combined xenon-dexmedetomidine anesthesia in children.
DISCUSSION CONCLUSIONS
Sevoflurane is the most frequently used anesthetic in young children, but has been indicated as an independent risk factor in the development of emergence delirium. Xenon and dexmedetomidine have both been associated with a reduction in the incidence of emergence delirium. Combining xenon and dexmedetomidine has never been described as a balanced-anesthesia technique in children. Our pilot study will therefore deliver important data required for future prospective clinical trials.
TRIAL REGISTRATION BACKGROUND
EudraCT, 2018-002258-56. Registered on 20 August 2018. https://www.clinicaltrialsregister.eu.

Identifiants

pubmed: 32245513
doi: 10.1186/s13063-020-4231-5
pii: 10.1186/s13063-020-4231-5
pmc: PMC7126401
doi:

Substances chimiques

Anesthetics, Combined 0
Anesthetics, Inhalation 0
Sevoflurane 38LVP0K73A
Xenon 3H3U766W84
Dexmedetomidine 67VB76HONO

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

310

Références

Anesthesiology. 2004 May;100(5):1138-45
pubmed: 15114210
Paediatr Anaesth. 2013 Apr;23(4):309-15
pubmed: 23464658
Anesthesiology. 2001 Apr;94(4):611-4
pubmed: 11379681
Br J Anaesth. 1996 Feb;76(2):179-85
pubmed: 8777094
Br J Anaesth. 2012 Jan;108(1):80-8
pubmed: 22139005
Paediatr Anaesth. 2017 Apr;27(4):399-408
pubmed: 28211134
Trials. 2015 Mar 04;16:74
pubmed: 25886748
Can J Anaesth. 1992 Sep;39(7):649-54
pubmed: 1394752
J Clin Anesth. 1999 Sep;11(6):466-70
pubmed: 10526824
Neurotoxicol Teratol. 2017 Mar - Apr;60:102-116
pubmed: 28065636
Cochrane Database Syst Rev. 2014 Sep 12;(9):CD007084
pubmed: 25212274
Anaesthesia. 2015 Apr;70(4):383-7
pubmed: 25764401
Anesth Analg. 2016 Mar;122(3):678-97
pubmed: 26273750
Paediatr Anaesth. 2016 Mar;26(3):239-48
pubmed: 26612740
Paediatr Anaesth. 2017 Dec;27(12):1210-1219
pubmed: 28872734
Clin Chem Lab Med. 2016 Oct 1;54(10):1671-80
pubmed: 26943607
Anaesth Intensive Care. 2008 Nov;36(6):807-13
pubmed: 19115649
J Clin Anesth. 1995 Feb;7(1):89-91
pubmed: 7772368
Stroke. 2000 Nov;31(11):2670-7
pubmed: 11062293
J Pediatr Intensive Care. 2017 Jun;6(2):117-122
pubmed: 31073434
Paediatr Anaesth. 2010 Aug;20(8):704-11
pubmed: 20497353
Anesthesiology. 2007 Apr;106(4):746-53
pubmed: 17413912
Curr Opin Anaesthesiol. 2014 Jun;27(3):309-15
pubmed: 24784918
Anesth Analg. 2002 Oct;95(4):889-92, table of contents
pubmed: 12351263
Br J Anaesth. 2018 Dec;121(6):1365-1368
pubmed: 30442266
Anesthesiology. 1980 Oct;53(4):351
pubmed: 7425366
Pediatr Crit Care Med. 2014 Mar;15(3):219-28
pubmed: 24366505
Paediatr Anaesth. 2014 Sep;24(9):987-93
pubmed: 24823715
Acta Anaesthesiol Scand. 2010 Jul;54(6):710-6
pubmed: 20003127
Eur J Anaesthesiol. 2010 Oct;27(10):906-11
pubmed: 20671557
Anesthesiology. 2003 Jan;98(1):6-13
pubmed: 12502972
Br J Anaesth. 2014 Jun;112(6):982-90
pubmed: 24727829
Anesthesiology. 2008 Jan;108(1):63-70
pubmed: 18156883
Anesth Analg. 2016 Sep;123(3):715-21
pubmed: 27167685
Br J Anaesth. 2017 Mar 1;118(3):335-343
pubmed: 28203739
Stroke. 2006 Feb;37(2):501-6
pubmed: 16373643
Br J Anaesth. 2016 Mar;116(3):377-83
pubmed: 26865130
Paediatr Anaesth. 2018 Aug;28(8):726-738
pubmed: 30004615

Auteurs

Sarah Devroe (S)

Department of Anesthesiology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. sarah.devroe@uzleuven.be.
Department of Pediatric and Congenital Cardiology, University Hospitals Leuven, Leuven, Belgium. sarah.devroe@uzleuven.be.

Lisa Devriese (L)

Department of Anesthesiology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.

Frederik Debuck (F)

Department of Anesthesiology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.

Steffen Fieuws (S)

I-Biostat, KU Leuven - University of Leuven, Leuven, Belgium.

Bjorn Cools (B)

Department of Pediatric and Congenital Cardiology, University Hospitals Leuven, Leuven, Belgium.
Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium.

Marc Gewillig (M)

Department of Pediatric and Congenital Cardiology, University Hospitals Leuven, Leuven, Belgium.
Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium.

Marc Van de Velde (M)

Department of Anesthesiology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium.

Steffen Rex (S)

Department of Anesthesiology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Department of Cardiovascular Sciences, Katholieke Universiteit (KU) Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH